NASDAQ:MGX Metagenomi (MGX) Stock Price, News & Analysis $2.72 -0.18 (-6.21%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.72▼$2.9550-Day Range$2.72▼$5.2552-Week Range$2.63▼$12.74Volume60,026 shsAverage Volume121,631 shsMarket Capitalization$101.90 millionP/E RatioN/ADividend YieldN/APrice Target$15.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Metagenomi alerts: Email Address Metagenomi MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside469.9% Upside$15.50 Price TargetShort InterestHealthy1.53% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.32Based on 14 Articles This WeekInsider TradingSelling Shares$18,043 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.04) to ($2.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.23 out of 5 starsMedical Sector488th out of 910 stocksBiological Products, Except Diagnostic Industry70th out of 155 stocks 3.4 Analyst's Opinion Consensus RatingMetagenomi has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMetagenomi has only been the subject of 3 research reports in the past 90 days.Read more about Metagenomi's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.53% of the float of Metagenomi has been sold short.Short Interest Ratio / Days to CoverMetagenomi has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Metagenomi has recently increased by 3.97%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMetagenomi does not currently pay a dividend.Dividend GrowthMetagenomi does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MGX. Previous Next 1.8 News and Social Media Coverage News SentimentMetagenomi has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Metagenomi this week, compared to 2 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Metagenomi insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,043.00 in company stock.Read more about Metagenomi's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Metagenomi are expected to grow in the coming year, from ($3.04) to ($2.86) per share.Price to Book Value per Share RatioMetagenomi has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Metagenomi's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsNASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...Click here to learn more >>> About Metagenomi Stock (NASDAQ:MGX)Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.Read More MGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MGX Stock News HeadlinesSeptember 7 at 9:25 AM | insidertrades.comInsider Selling: Metagenomi, Inc. (NASDAQ:MGX) CFO Sells 6,265 Shares of StockSeptember 7 at 9:41 AM | markets.businessinsider.comBuy Rating on Metagenomi, Inc. for Promising Hemophilia A Gene Editing Strategy and Strong Financial PositionSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.September 7 at 4:40 AM | benzinga.comPeeling Back The Layers: Exploring Metagenomi Through Analyst InsightsSeptember 7 at 4:29 AM | americanbankingnews.comMetagenomi (NASDAQ:MGX) Earns "Buy" Rating from Chardan CapitalSeptember 5 at 3:37 AM | markets.businessinsider.comBuy Rating Justified by Metagenomi’s Promising Gene Therapy and Strategic Market Positioning in Hemophilia A TreatmentSeptember 5 at 3:37 AM | markets.businessinsider.comBuy Rating Justified by Metagenomi’s Breakthrough in Long-term Gene Therapy Efficacy and SafetySeptember 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Metagenomi, Inc. - MGXSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.September 3, 2024 | globenewswire.comMetagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve MonthsAugust 30, 2024 | americanbankingnews.comMetagenomi, Inc. (NASDAQ:MGX) Receives $15.50 Average Target Price from BrokeragesAugust 29, 2024 | globenewswire.comMetagenomi Presents AI-Enabled Advancements of SMART Editing Platform at the Cold Spring Harbor Laboratory CRISPR Frontiers ConferenceAugust 28, 2024 | globenewswire.comMetagenomi to Participate in Upcoming Investor ConferencesAugust 26, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Metagenomi, Inc. - MGXAugust 25, 2024 | stockhouse.comMetagenomi Inc Is Being Inquired Into For Securities Fraud And The Schall Law Firm Seeks Shareholder ParticipationAugust 22, 2024 | markets.businessinsider.comMetagenomi, Inc. Maintains Buy Rating Amidst Competitive Challenges and Strong Financial OutlookAugust 17, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Metagenomi, Inc. - MGXAugust 14, 2024 | globenewswire.comMetagenomi Reports Business Updates and Second Quarter 2024 Financial ResultsSee More Headlines Receive MGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Metagenomi and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MGX Previous SymbolNASDAQ:MGX CUSIPN/A CIK1785279 Webwww.metagenomi.co Phone510-871-4880FaxN/AEmployees236Year FoundedN/APrice Target and Rating Average Stock Price Target$15.50 High Stock Price Target$25.00 Low Stock Price Target$6.00 Potential Upside/Downside+469.9%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio5.82 Quick Ratio5.82 Sales & Book Value Annual Sales$55.93 million Price / Sales1.82 Cash FlowN/A Price / Cash FlowN/A Book Value$7.20 per share Price / Book0.38Miscellaneous Outstanding Shares37,464,000Free FloatN/AMarket Cap$101.90 million OptionableN/A BetaN/A 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Brian Charles Thomas Ph.D. (Age 55)Co-Founder, CEO & Chairman of the Board Comp: $859.34kDr. Jian Irish M.B.A. (Age 60)Ph.D., President, COO & Director Comp: $729.82kDr. Sarah B. Noonberg M.D. (Age 56)Ph.D., Chief Medical Officer Comp: $591.49kDr. Jak Knowles M.D.Co-Founder & Member of Scientific Advisory BoardMs. Pamela M. Wapnick M.B.A. (Age 58)Chief Financial Officer Dr. Luis G. Borges Ph.D. (Age 62)Chief Scientific Officer More ExecutivesKey CompetitorsTourmaline BioNASDAQ:TRMLCryoportNASDAQ:CYRXFate TherapeuticsNASDAQ:FATEC4 TherapeuticsNASDAQ:CCCCKorro BioNASDAQ:KRROView All CompetitorsInsiders & InstitutionsPamela WapnickSold 6,265 sharesTotal: $18,043.20 ($2.88/share)Novo Holdings A SBought 60,825 shares on 8/20/2024Ownership: 4.805%Point72 Asset Management L.P.Sold 272,098 shares on 8/19/2024Ownership: 0.264%Frazier Life Sciences Management L.P.Sold 33,333 shares on 8/16/2024Ownership: 0.656%Marshall Wace LLPSold 14,388 shares on 8/14/2024Ownership: 0.450%View All Insider TransactionsView All Institutional Transactions MGX Stock Analysis - Frequently Asked Questions How have MGX shares performed this year? Metagenomi's stock was trading at $10.31 at the beginning of 2024. Since then, MGX stock has decreased by 73.6% and is now trading at $2.72. View the best growth stocks for 2024 here. How were Metagenomi's earnings last quarter? Metagenomi, Inc. (NASDAQ:MGX) announced its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $0.30. The firm had revenue of $20.01 million for the quarter, compared to analyst estimates of $14.80 million. When did Metagenomi IPO? Metagenomi (MGX) raised $94 million in an initial public offering on Friday, February 9th 2024. The company issued 6,250,000 shares at $15.00 per share. When did the company's lock-up period expire? Metagenomi's lock-up period expired on Wednesday, August 7th. Metagenomi had issued 6,250,000 shares in its initial public offering on February 9th. The total size of the offering was $93,750,000 based on an initial share price of $15.00. Since the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted. Who are Metagenomi's major shareholders? Metagenomi's top institutional shareholders include Novo Holdings A S (4.80%), Frazier Life Sciences Management L.P. (0.66%), Marshall Wace LLP (0.45%) and Point72 Asset Management L.P. (0.26%). Insiders that own company stock include Holdings A/S Novo and Pamela Wapnick. View institutional ownership trends. How do I buy shares of Metagenomi? Shares of MGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MGX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metagenomi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
